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Background and aims: Stereotactic body radiotherapy (SBRT) is a relatively new treatment for liver tumor. The
outcomes of SBRT for liver tumor unfit for ablation and surgical resection were evaluated.
Methods: Liver tumor patients treated with SBRT in seven Japanese institutions were studied retrospectively. Patients
given SBRT for liver tumor between 2004 and 2012 were collected. Patients treated with SBRT preceded by trans-arterial
chemoembolization (TACE) were eligible. Seventy-nine patients with hepatocellular carcinoma (HCC) and 51 patients with
metastatic liver tumor were collected. The median biologically effective dose (BED) (α/β = 10 Gy) was 96.3 Gy for
patients with HCC and 105.6 Gy with metastatic liver tumor.
Results: The median follow-up time was 475.5 days in patients with HCC and 212.5 days with metastatic liver tumor.
The 2-year local control rate (LCR) for HCC and metastatic liver tumor was 74.8% ± 6.3% and 64.2 ± 9.5% (p = 0.44). The
LCR was not different between BED10≥ 100 Gy and < 100 Gy (p = 0.61). The LCR was significantly different between
maximum tumor diameter > 30 mm vs. ≤ 30 mm (64% vs. 85%, p = 0.040) in all 130 patients. No grade 3 laboratory
toxicities in the acute, sub-acute and chronic phases were observed.
Conclusions: There was no difference in local control after SBRT in the range of median BED10 around 100 Gy for
between HCC and metastatic liver tumor. SBRT is safe and might be an alternative method to resection and ablation.
Summary: There was no difference in local control after SBRT in the range of median BED10 around 100 Gy for
between HCC and metastatic liver tumor and SBRT is safe and might be an alternative method to resection and
ablation.
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ablative radiotherapyIntroduction
In Japan, an infection rate of the hepatitis C is high, and
there are many hepatocellular carcinoma (HCC) cases. The
liver is also a common lesion of metastases from most
common solid malignancies. According to clinical practice
guidelines from Japan, resection, radiofrequency ablation
(RFA), and liver transplantation are the available curative
options for HCC [1]. Recently, stereotactic body radiother-
apy (SBRT) has become a treatment option for patients* Correspondence: yamachan07291973@yahoo.co.jp
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article, unless otherwise stated.with liver tumor who are not eligible for surgery, RFA, or
liver transplantation. Although HCC doesn’t really have
bad radiation sensitivity [2], what’s happening now is that
SBRT for HCC has not been performed very much. One
of the reasons is that the role of radiotherapy (RT) for liver
tumors has been limited due to the risk of radiation-
induced liver disease (RILD) [3]. However, technological
advances have made it possible for radiation to be delivered
to small liver tumors while reducing the risk of RILD [4].
Resection, RFA, or trance-catheter arterial chemoemboli-
zation (TACE) are often performed for HCC and liver me-
tastasis in Japan. However, only 10–20% of HCC patients
have a resectable disease [5]. A drawback to RFA is thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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perform [6]. It is only the case with a central lesion of the
liver, with direct invasion into the vessels, and/or that an
effect of TACE was insufficient to be introduced to SBRT.
In patients with centrally located HCC with chronic hepa-
titis or cirrhosis, major resection is often contraindicated
due to insufficient residual liver volume [7]. RFA is there-
fore often contraindicated for HCC in those areas, which
are located in and near the hepatic portal vein or central
bile duct [8] and abutting the diaphragm [6]. Additionally,
the risk of neoplastic seeding along the needle track after
RFA has been reported [9].
SBRT offers an alternative, non-invasive approach to the
treatment of liver metastasis. The goal of SBRT is to deliver
a high dose to the target, thereby providing better local
tumor control, while limiting dose to surrounding healthy
tissue, thereby potentially decreasing complication rates.
Early applications of SBRT to liver metastases have been
promising [10-20]. While these data establish the safety of
stereotactic radiation therapy for liver metastases, all SBRT
treatments must be performed cautiously given the chal-
lenges of organ motion and the low radiation tolerance of
the surrounding hepatic parenchyma.
Takeda et al. [21] reported that local control rate (LCR)
after SBRT for lung metastases from colorectal cancer
with a 2-year LCR of 72% was worse than that for primary
lung cancer. We hypothesized that the same thing as this
might apply to HCC and liver metastasis and, in other
words, LCR after SBRT for liver metastases might be
worse than that for HCC.
Because there was little number of cases that has
performed liver SBRT in every each institution, we
wanted to research results and a side effect as a whole in
many institutions. The purpose of this study was to retro-
spectively evaluate the outcomes, mainly concerning local




This is a retrospective study to review 130 patients with
primary or metastatic liver cancers treated at seven in-
stitutions extracted from the database of Japanese Radio-
logical Society multi-institutional SBRT study group
(JRS-SBRTSG). The investigation period was from May
2004 to November 2012.
The diagnosis of HCC depended mostly on imaging
studies, because candidates for SBRT were unfeasible for
pathological confirmation. During follow-up of patients
with liver disease, nodules ≥1 cm were diagnosed as
HCC based on the typical hallmarks (hyper-vascular in
the arterial phase with washout in the portal, venous or
delayed phases) from imaging studies, which included
a combination of contrast-enhanced ultrasonography,4-phase multi-detector computed tomography (CT),
dynamic contrast-enhanced magnetic resonance im-
aging (MRI), and CT during hepatic arteriography and
arterio-portography studies. The diagnosis was estab-
lished according to a review [22] and clinical practice
guidelines [23,24]. The eligibility of SBRT for HCC was
a single lesion in principle.
The diagnosis of metastatic liver tumor was confirmed
by diagnostic imaging including ultrasound, CT, and/or
MRI. The eligibility of SBRT for metastatic liver tumor
was without other lesions and in less than four.
Patient and tumor characteristics were shown in
Table 1. HCC included 79 cases and the liver metastases
included 51 cases. The Child-Pugh score before SBRT
for HCC was 84.8% in grade A, 11.4% in grade B, and
1.3% in grade C. Ischemic HCC was 16/79 cases (20%)
and plethoric HCC was 55/79 cases (70%). The median
alpha-fetoprotein (AFP) (ng/mL) and des-gamma car-
boxy prothrombin (PIVKA-II) (AU/mL) value before
SBRT for evaluable 73 patients with HCC were 12.7
(range; 0.8-8004) and 35 (range; 3.1-16900). The median
indocyanine green retention rate at 15 min (ICG15) value
before SBRT for evaluable 25 patients with HCC was
21.2% (range; 3–56.2%). This SBRT was the first treatment
in 26/79 cases (33%) and was the first treatment about the
same lesion as this SBRT in the additional 7 cases. About
the primary tumor site of liver metastases, colo-rectum was
58.8%, lung was 9.8%, and stomach was 9.8%. The number
of SBRT lesions was from 1 to 4 (solitary was 41/51 cases)
for liver metastasis.
Treatment
For treatment planning, abdominal pressure corsets such
as body shell or vacuum cushion such as blue back were
used, and it was confirmed that tumor motion was <1 cm.
Then, the gross tumor volume (GTV) was delineated on
the both inspiratory and expiratory planning CT images
in the case of respiratory depression method. The breath-
holding method was used in 36 cases, gating method in 10
cases, and respiratory depression method in 25 cases about
HCC patients. The planning target volume (PTV) was con-
figured considering respiratory movement, a set-up margin,
and a sub-clinical margin (Figure 1). SBRT was performed
with an X-ray beam linear accelerator of 6 MV. The total
dose was delivered depending on judgment each institu-
tion. A collapsed cone (CC) convolution, superposition
algorithm, or analytical anisotropic algorithm (AAA) was
used for dose calculations.
The mode value of total irradiated dose was 48 Gy in
4 fractions (38/79 cases) (from 40 Gy in 4 fractions to
60 Gy in 10 fractions) for HCC and 48 Gy in 4 fractions
(12/51 cases) and 52 Gy in 4 fractions (16/51 cases)
(from 30 Gy in 3 fractions to 60 Gy in 8 fractions) for
metastatic liver tumor. The biologically effective dose
Table 1 Patient and tum or characteristics of SBRT
Liver metastasis N % HCC N %
51 100 79 100
Primary cancer Stage
Colon cancer 21 41.2 I 29 36.7
Rectal cancer 9 17.6 II 21 26.6
Lung cancer 5 9.8 III 5 6.3
Gastric cancer 5 9.8 IV 2 2.5
Cervical cancer 3 5.9 Recurrence 11 13.9
Breast cancer 3 5.9 NE 11 13.9
Pancreatic cancer 3 5.9
Bile duct cancer 1 2.0
Skin cancer 1 2.0
Number of SRT Chilid-Pugh
before SBRT
Single SRT 41 80.4 A 67 84.8
Two places 8 15.7 B 9 11.4
Tree 1 2.0 C 1 1.3
Four 1 2.0 NE 2 2.5
Sex
Female 17 33.3 19 24






0 32 62.7 34 43.0
1 13 25.5 39 49.4
2 5 9.8 4 5.1










Abbreviation: NE not evaluable.
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for patients with HCC and 56–134 Gy (median: 106 Gy)
with metastatic liver tumor (Table 1). The formula about
BED10 was used; BED (Gy10) = nd (1 + d/α/β). In all 130
cases, CT registration like cone beam CT was performed
each treatment.SBRT was delivered using multiple non-coplanar static
beams (using > 7 non-coplanar fields) generated by a linear
accelerator or volumetric modulated arc therapy. Daily
image guidance, by using either orthogonal X-rays or
onboard CT imaging, was used to re-localize the target
before treatment delivery.
Trans-catheter arterial chemoembolization (TACE) in 7
HCC patients, FOLFILI regimen (folinic acid, fluorouracil,
plus irinotecan) in a metastatic liver tumor patient, or
TAXOL® (paclitaxel) in a metastatic liver tumor patient
was performed before SBRT. Oral TS-1 was combined
concurrently with SBRT in an HCC patient.
Follow up
Patients were seen monthly for 1 year after SBRT and tri-
monthly thereafter. Laboratory tests were done at every
visit. Treatment responses and intrahepatic recurrences
were evaluated with dynamic contrast-enhanced CT or
MRI every 3 months with modified Response Evaluation
Criteria in Solid Tumors (mRECIST) [25]. Toxicity was
evaluated with the Common Terminology Criteria for Ad-
verse Events (CTCAE), version 4.0. Acute and sub-acute
toxicities were defined as adverse events occurring within
3 months and 3–6 months, respectively, after SBRT. Late
toxicities related with liver and other toxicities were defined
as those occurring after 6–12 months and from 6 months
to last follow-up, respectively. Laboratory tests included
aspartate aminotransferase, total bilirubin, platelet count,
and albumin.
Local recurrence was defined as progressive disease in
mRECIST or the new appearance of a lesion within the
PTV, and local control was defined as free of local re-
currence. Local control was defined as freedom from
local progression by mRECIST.
Statistical analysis
Control and survival rates were calculated with Kaplan-
Meier analysis. Log-rank testing was used to compare
outcomes between the subsets of patients analyzed. Cox
proportional hazards regression analysis was used for
multivariate analysis. A p-value of <0.05 was considered
significant. Data were analyzed with SPSS Statistics 20.0
(IBM Corp., Armonk, NY, USA). The points on survival
curves by Kaplan Meier are a censored case.
Results
Eligible patients
The median follow-up time was 475.5 days (range;
101–2050 days) in patients with HCC and 212.5 days
(range; 26–2713 days) with metastatic liver tumor. SBRT
was performed as scheduled and was feasible in all pa-
tients. At the last follow-up, 48/79 cases (61%) were
survival and 31/79 (39%) were dead for HCC and 42/51
Figure 1 Dose distribution of SBRT for liver tumor. Sky blue line = ITV, purple line = PTV, red area = over 95% dose, green area = 90-95%, blue
area = 80-90%, yellow area = 70-80%, purple area = 60-70%, sky blue area = 50-60%, orange area = 30-40%.
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for metastatic liver tumors.
Treatment outcomes
Clinical results were shown in Table 2. As to the initial
local effect, complete response (CR) and partial responseTable 2 Clinical results of SBRT
N % N %
Liver metastasis HCC
First local effect
CR 15 29.4 36 45.6
PR 23 45.1 28 35.4
MR 2 3.9 0 0
NC 6 11.8 9 11.4
PD 0 0 4 5.1
NE 5 9.8 2 2.5
Local progress
With 10 19.6 14 17.7
Without 37 72.5 63 79.7
NE 4 7.8 2 2.5
Abbreviation: CR complete response, PR partial response, MR minor response,
NC no change, PD progress disease, NE not evaluable.(PR) were 45.6% and 35.4% in SBRT for HCC and 29.4%
and 45.1% for metastatic liver tumor, respectively.
The 2-year cumulative LCR for HCC and metastatic liver
tumor was 74.8% ± 6.3% (standard error) and 64.2 ± 9.5%
(p = 0.44) (Figure 2). The LCR was not different between
BED10 ≥ 100 Gy (69.0% ± 7.6% at 2 years) vs. < 100 Gy
(72.4% ± 7.7%) in all 130 patients (p = 0.61) (Figure 3). The
LCR was not different between HCC (68.2% ± 11.2%) vs.
liver metastasis (68.3% ± 11.2%) in 70 patients with the
higher BED10 ≥ 100 Gy (p = 0.96). The LCR was not differ-
ent between BED10 ≥ 100 Gy (68.3% ± 11.2%) vs. < 100 Gy
(46.5% ± 16.9%) in 51 patients with liver metastasis
(68.2% ± 11.2% vs. 79.2% ± 7.7%, p = 0.72) and in 79
patients with HCC (p = 0.43). In all 130 patients, the
LCR was not different between maximum tumor
diameter > 20 mm vs. ≤ 20 mm (70.6% ± 7.6% vs. 83.5% ±
7.6%, p = 0.28) and ≥ 40 mm vs. < 40 mm (55.4% ± 17.2%
vs. 79.8% ± 5.1%, p = 0.32) except for > 30 mm vs. ≤ 30 mm
(64.1% ± 9.1% vs. 85.2% ± 5.6%, p = 0.040) (Figure 4).
The LCR was not different between BED10 ≥ 100 Gy
(66.2% ± 33.8%) vs. < 100 Gy (62.3% ± 12.6%) in 41
patients with the bigger tumor diameter > 30 mm (p =
0.78). The LCR was not different between older (>70 y.o.)
vs. younger (≤70 y.o.) (74.4% ± 6.2% vs. 70.6% ± 8.9%,
p = 0.76).
Figure 2 Local control curves between SBRT for hepatic cell
carcinoma and metastatic liver tumor. The points on survival
curves are a censored case.
Figure 4 Local control curves between maximum tumor
diameter > 30 mm and </=30 mm. The points on survival curves
are a censored case.
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regression analysis), the maximum tumor diameter >
30 mm vs. ≤ 30 mm (other covariates were BED10 ≥
100 Gy vs. <100 Gy of p = 0.70, age >70 y.o. vs. ≤ 70 y.o. of
p = 0.73, HCC vs. metastatic liver tumor of p = 0.52) was
the only significant factor for LCR (p = 0.047, 95% CI =
1.014-7.546).
The scatter diagram between BED10 and local control
time was shown in Figure 5. There was no correlation
between BED10 and local control time. We didn’t show
the fact that the higher BED10 was, the longer local con-
trol time was.
The 2-year overall survival (OS), cause specific survival
(CSS), disease free survival (DFS), and distant metastatic
free survival (DMF) were 52.9% ± 7.1%, 69.0% ± 6.9%,
39.9% ± 6.9%, and 76.3% ± 6.6% in 79 patients with HCC,
respectively (Figure 6). The number of patients at risk wasFigure 3 Local control curves between BED (10) > 100 Gy and
< 100 Gy. The points on survival curves are a censored case.43, 21, 9, and 3 at 1-, 2-, 3-, and 4-year in OS, respectively.
The 2-year OS was 71.9% ± 9.4% in 51 patients with meta-
static liver tumor.
The 2-year cumulative LCR for HCC (n = 79) vs. meta-
static liver tumor from colorectal cancer (n = 30) vs. from
other cancers (n = 21) was 74.1% ± 6.2% vs. 54.2% ± 11.8%
vs. 87.5% ± 11.7% (p = 0.18 by comparison among three
groups, p = 0.12 between colorectal and other cancers,
and p = 0.16 between HCC and colorectal cancer).
Treatment-related toxicity
All SBRT were completed without toxicity during RT
period. There was no Grade 5 toxicity. Nine patients (7%)
experienced Grade 2–4 gastrointestinal toxicity. Three
patients had Grade 2 gastric inflammations at both 1 Mo
(40 Gy in 4 fractions and 60 Gy in 10 fractions) and one
gastric ulcer at 27 Mo (60 Gy in 10 fractions). Four had
Grade 3 intestinal tract bleedings at 5 Mo (50 Gy in 5 frac-
tions) and 6 Mo (40 Gy in 4 fractions) and transverse
colon ulceration at 5 Mo (60 Gy in 10 fractions) and duo-
denal ulcer at 17 Mo (48 Gy in 4 fractions) without
chemotherapy in all 4 cases. One patient had Grade 4
gastro-duodenal artery rupture at 6 Mo after SBRT of
48 Gy in 4 fractions without chemotherapy. One patient
complained of chest wall pain after SBRT of 45.2 Gy in 4
fractions combined with TACE.
No significant (≥ grade 3) liver enzyme elevation was
observed during treatment. No classic RILD was
observed.
Discussion
This is a retrospective study to review 130 patients with
primary or metastatic liver cancers treated at 20 institu-
tions extracted from the database of JRS-SBRTSG. The
primary aim of the paper is to report outcome in terms
Figure 5 Scatter diagram between BED10 (Gy) and local control time (days).
Figure 6 Local control curves among HCC, liver metastases
from colorectal cancer, and from other cancers.
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in this study of 53% for HCC (n = 79) and 72% for liver
metastases (n = 51) at 2 year after SBRT were almost
satisfactory (median follow-up was 16 months), but
there were various biases in that the candidates included
frail patients contraindicated due to decompensated cirrho-
sis and older patients with a median age of 73 years. It was
the reason why only LCR was performed for the factor
analysis in this study.
The local controls after stereotactic body radiotherapy
for liver tumor were 65% to 100% in HCC and 56% to
100% in metastatic liver tumor. Results of phase I/II
studies and retrospective series of SBRT for HCC patients
indicated high local control rates of 90-100% [26-29]. In
this study, local recurrence was seen at within 8 months
in almost all cases and at 20 to 23 months in some cases.
The LCR of HCC in this study was slightly poor and could
hardly have been more different from that of metastatic
liver tumor. We showed the summary of LC after SBRT
for liver tumor in Table 3.
Table 3 Summary of local control after stereotactic body radiotherapy for liver tumor
First author Ref. Target Year Case no. Total RT dose Fr no. LC Timing of LC
Blomgren H [30] HCC 1995 20 15-45 Gy 1-5 80% 1.5-38 mo
Tse RV [26] HCC & IHC 2008 41 36 Gy 6 65% 12 mo
Cardenes HR [31] HCC 2010 17 36-48 Gy 3 100% 10-42 mo
Kwon JH [32] HCC 2010 42 30-39 Gy 3 68% 36 mo
Louis C [33] HCC 2010 25 45 Gy 3 95% 24 mo
Seo YS [34] HCC 2010 38 33-57 Gy 3-4 66% 24 mo
Andolino DL [28] HCC 2011 60 40 Gy, 44 Gy 5 90% 24 mo
3
Kang JK [29] HCC 2012 50 42-60 Gy 3 95% 24 mo
Takeda A [21] HCC 2013 63 35-40 Gy 5 92% 36 mo
Herfarth KK [10] ML 2001 37 14-26 Gy NA 78% 5.7 mo
Wada H [11] ML 2004 34 45 Gy 3 86% 12 mo
Kavanagh BD [12] ML 2006 36 60 Gy 3 93% 18 mo
Hoyer M [13] ML 2006 64 45 Gy 3 63% 24 mo
Katz AW [14] ML 2007 69 30-55 Gy NA 57% 20 mo
Lee MT [16] ML 2009 68 27.7-60 Gy 6 71% 12 mo
Rusthoven KE [17] ML 2009 47 36-60 Gy 3 92% 24 mo
Rule W [18] ML 2011 27 30 Gy, 3 56% 24 mo
50 Gy, 5 89%
60 Gy 5 100%
Chang DT [19] ML 2011 65 46-52 Gy 3 90% 12 mo
Fumagalli I [20] ML 2012 90 15 Gy 3 66% 24 mo
Abberiviation: HCC hepatocellular carcinoma, IHC intrahepatic cholangiocarcinoma, ML metastatic liver tumor, RT radiotherapy, Fr = fractions, LC = local
control, mo months.
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the present report because patients who died without the
evidence of local recurrence were excluded. Since the pure
LCR want to be calculated, the patients who died without
local recurrence were treated as a censored case. Takeda
et al. [21] reported that LCR after SBRT for lung metasta-
ses from colorectal cancer with a 2-year LCR of 72% was
worse than that for primary lung cancer and also in the
present study, LCR for liver metastases from colorectal
cancer was slightly worse than that for HCC or liver
metastases from other cancers, although there was no
significant difference. The patient number at this time
may be too small to detect the significant differences
on LCR among three groups.
To improve our results of local control and so on, we
may increase radiation dose. The median BED10 in this
study was 96 Gy for patients with HCC and 106 Gy with
metastatic liver tumor. Although it is natural that BED10
is over 100 Gy in the SBRT for lung tumor, the fact may
be not true of the SBRT for liver tumor. Although the
aim of SBRT is to deliver a high ablative dose to destroy
tumor cells, the optimal treatment dose should be deter-
mined based on both tumor control and long-term safetybecause radiation damage to the normal liver tissue is
dose-volume-dependent [35,36]. In SBRT for liver tumors,
the prescribed dose and fraction vary across studies,
ranging from 24–60 Gy in 2–6 fractions, and most
studies focused predominantly on liver metastases [37].
Since metastatic lung tumors require dose escalation due
to relatively low radio-sensitivity [38], increasing the dose
to metastatic liver tumors appears to be reasonable, and
patients with normal liver function treated with SBRT
have rarely developed RILD. In contrast, dose escalation
in HCC patients with decompensated cirrhotic liver dis-
ease may be disadvantageous with respect to normal liver
tolerance. A dose-control relationship has been described
for patients treated with SBRT for liver and lung metasta-
ses. In an analysis of 246 lesions treated with three-fraction
SBRT for primary or metastatic tumors within the lung or
liver, McCammon et al. [39] demonstrated significant im-
provement in local control with increasing dose and the
3-year local control rate in their series was 89.3% for those
lesions that received 54 to 60 Gy versus 59% and 8.1% for
lesions that received 36 to 53.9 Gy and less than 36 Gy,
respectively (p < 0.01). Tekeda et al. [40] used 35–40 Gy
in 5 fractions based on baseline liver function and liver
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HCC patients.
By multivariate analysis, the maximum tumor diam-
eter > 30 mm vs. ≤ 30 mm was only one prognostic
factor for LCR. According to Rusthoven et al. [17], ac-
tuarial in-field local control rates at one & two years
after SBRT of 60 Gy in 3 fractions for the treatment of
47 patients with one to three hepatic metastases (63
lesions) were 95% & 92% and 2-year local control was
100% among lesions with maximal diameter of 3 cm
or less.
However, this study has some limitations in that it is a
retrospective and multi-institutional series with a rela-
tively short follow-up period. The group is very heteroge-
neous including primary and metastatic liver tumors. That
is why the irradiated dose and the follow-up method are
inconsistent, too. The reason why there was no difference
by the stratification of irradiated dose may be that in
this study the problem of algorithm or prescription
point can be integrated. We are planning to start a
multi-institutional prospective large-scale clinical trial
that standardized these factors.
Conclusions
There was no difference in LCR between liver metastasis
vs. HCC and the higher vs. lower BED10 against SBRT for
liver cancer except for the bigger vs. smaller tumor diam-
eter. SBRT is a safe treatment and may be an alternative
option for patients with liver tumor unfit for resection or
RFA. Further prospective studies are warranted to validate
the effect of SBRT for liver tumor.
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